Enhertu Reimbursement Analysis: Navigating Cost...

By João L. Carapinha

June 5, 2025

The Dutch Healthcare Institute (ZIN) has recommended trastuzumab deruxtecan (Enhertu) for inclusion in the Netherlands’ basic insurance package for HER2-low metastatic breast cancer. This recommendation is contingent on a pric...
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global He...
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
EU Establishes Expert Panel for Orphan Paediatric Devices
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China
First At-Home HPV Testing Approval: FDA Clears Teal Wand
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...